Source: The Journal of Pathology : Clinical Research. Unidade: FMRP
Subjects: NEOPLASIAS OVARIANAS, QUIMIOTERAPIA, IMUNIDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AU, Katrina K. et al. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. The Journal of Pathology : Clinical Research, v. 2, n. 4, p. 259-270, 2016Tradução . . Disponível em: https://doi.org/10.1002/cjp2.55. Acesso em: 01 maio 2026.APA
Au, K. K., Page, C. L., Ren, R., Meunier, L., Clément, I., Tyrishkin, kathrin, et al. (2016). STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. The Journal of Pathology : Clinical Research, 2( 4), 259-270. doi:10.1002/cjp2.55NLM
Au KK, Page CL, Ren R, Meunier L, Clément I, Tyrishkin kathrin, Peterson N, Kendall-Dupont J, Childs T, Francis J-A, Graham CH, Craig AW, Squire JA, Mess-Masson A-M, Koti M. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer [Internet]. The Journal of Pathology : Clinical Research. 2016 ; 2( 4): 259-270.[citado 2026 maio 01 ] Available from: https://doi.org/10.1002/cjp2.55Vancouver
Au KK, Page CL, Ren R, Meunier L, Clément I, Tyrishkin kathrin, Peterson N, Kendall-Dupont J, Childs T, Francis J-A, Graham CH, Craig AW, Squire JA, Mess-Masson A-M, Koti M. STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer [Internet]. The Journal of Pathology : Clinical Research. 2016 ; 2( 4): 259-270.[citado 2026 maio 01 ] Available from: https://doi.org/10.1002/cjp2.55
